{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:54:08Z","timestamp":1782129248345,"version":"3.54.5"},"reference-count":185,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Conventional cancer therapies are limited by systemic toxicity, poor selectivity,\nand drug resistance. Bacterial proteins, such as azurin, represent a promising alternative due to\ntheir tumor selectivity, low immunogenicity, and multifunctional mechanisms. This review highlights\nrecent progress in azurin-based anticancer strategies, including mechanisms of action, structural\nmodifications, and integration with peptide systems, nanotechnology, and gene therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A search for articles using the keywords \"azurin, cancer\" was conducted on the Google\nScholar and PubMed databases, with an emphasis on the years 2023-2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Azurin and its peptide derivative p28 selectively target cancer cells by stabilizing p53, inducing\napoptosis, and arresting the cell cycle, while also modulating key signaling pathways. Structural\nfeatures of azurin enable interactions with multiple molecular targets, and p28 enhances cellular\nuptake and sensitizes tumors to chemotherapeutics. Advanced delivery platforms, including engineered\nbacteria (E. coli Nissle 1917, S. typhimurium VNP-20009), chimeric peptides, and nanocarriers,\nimprove tumor targeting and therapeutic outcomes. Preclinical models and clinical trials demonstrate\nlow toxicity and efficacy against various solid tumors and gliomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Evidence supports azurin as a versatile anticancer agent with unique advantages over\nconventional therapies. Its compatibility with delivery innovations enhances precision and minimizes\nsystemic toxicity. However, further optimization, large-scale clinical validation, and long-term safety\nstudies are required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Azurin and its derivatives provide a promising platform for anticancer therapy, offering\ntumor specificity, low toxicity, and synergy with multiple treatment modalities. Their integration into\nadvanced delivery and genetic systems may significantly improve cancer treatment and recurrence\nprevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501415032251108152158","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T20:26:06Z","timestamp":1769891166000},"page":"291-311","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Possible Applications of Azurin, a Copper-Containing Protein, in Cancer Treatment: Prospects and Challenges"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-8664","authenticated-orcid":true,"given":"Ekaterina E.","family":"Karmanova","sequence":"first","affiliation":[{"name":"Federal Research Center Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences,Institute of Cell Biophysics RAS, Institutskaya Str. 3, Pushchino, Moscow Region, 142290, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-9858","authenticated-orcid":true,"given":"Ruslan G.","family":"Goncharov","sequence":"additional","affiliation":[{"name":"Federal Research Center Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences,Institute of Cell Biophysics RAS, Institutskaya Str. 3, Pushchino, Moscow Region, 142290, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-3833","authenticated-orcid":true,"given":"Dmitriy E.","family":"Burmistrov","sequence":"additional","affiliation":[{"name":"Prokhorov General Physics Institute of the Russian Academy of Sciences, Vavilov Str. 38, Moscow, 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-6730","authenticated-orcid":true,"given":"Anatoly V.","family":"Chernikov","sequence":"additional","affiliation":[{"name":"Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Institutskaya Str. 3, Pushchino, Moscow Region, 142290, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-5481","authenticated-orcid":true,"given":"Vladimir I.","family":"Novoselov","sequence":"additional","affiliation":[{"name":"Federal Research Center Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences,Institute of Cell Biophysics RAS, Institutskaya Str. 3, Pushchino, Moscow Region, 142290, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5362-4269","authenticated-orcid":true,"given":"Mars G.","family":"Sharapov","sequence":"additional","affiliation":[{"name":"Federal Research Center Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences,Institute of Cell Biophysics RAS, Institutskaya Str. 3, Pushchino, Moscow Region, 142290, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"Bray F.","year":"2024","unstructured":"Bray F.; Laversanne M.; Sung H.; Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2024,74(3),229-263","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1134\/S0006350924701161","volume":"69","author":"Sharapov M.G.","year":"2024","unstructured":"Sharapov M.G.; Karmanova E.E.; Gudkov S.V.; Mechanisms of cancer cell radioresistance: Modern trends and research prospects. Biophysics  2024,69(6),1064-1088","journal-title":"Biophysics"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"105384","DOI":"10.1016\/j.jddst.2024.105384","volume":"93","author":"Samantaray A.","year":"2024","unstructured":"Samantaray A.; Dhamodharan D.; Thanigaivel S.; Pongen Y.L.; Thirumurugan D.; Byun H.S.; Novel insight into cancer treatment: Recent advances and new challenges. J Drug Deliv Sci Technol  2024,93,105384","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"20503121211034366","DOI":"10.1177\/20503121211034366","volume":"9","author":"Debela D.T.","year":"2021","unstructured":"Debela D.T.; Muzazu S.G.Y.; Heraro K.D.; New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med  2021,9,20503121211034366","journal-title":"SAGE Open Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"12931","DOI":"10.3390\/ijms241612931","volume":"24","author":"Nh\u00e0n N.T.T.","year":"2023","unstructured":"Nh\u00e0n N.T.T.; Yamada T.; Yamada K.H.; Peptide-based agents for cancer treatment: Current applications and future directions. Int J Mol Sci  2023,24(16),12931","journal-title":"Int J Mol Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12913-022-08981-5","volume":"23","author":"Hamad A.","year":"2023","unstructured":"Hamad A.; Elazzazy S.; Bujassoum S.; Applying value-based strategies to accelerate access to novel cancer medications: Guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP). BMC Health Serv Res  2023,23(1),15","journal-title":"BMC Health Serv Res"},{"key":"ref=7","first-page":"205","volume":"6","author":"Nauts H.C.","year":"1946","unstructured":"Nauts H.C.; Swift W.E.; Coley B.L.; The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res  1946,6,205-216","journal-title":"Cancer Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s42003-022-04395-5","volume":"6","author":"Choi J.K.","year":"2023","unstructured":"Choi J.K.; Naffouje S.A.; Goto M.; Cross-talk between cancer and Pseudomonas aeruginosa mediates tumor suppression. Commun Biol  2023,6(1),16","journal-title":"Commun Biol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/0109298673253414231127162817","volume":"32","author":"Pyla M.","year":"2025","unstructured":"Pyla M.; Kankipati S.; Sumithra B.; Bacterial proteins and peptides as potential anticancer agents: A novel search for protein-based therapeutics. Curr Med Chem  2025,32(7),1235-1263","journal-title":"Curr Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.trecan.2020.11.004","volume":"7","author":"Sieow B.F.L.","year":"2021","unstructured":"Sieow B.F.L.; Wun K.S.; Yong W.P.; Hwang I.Y.; Chang M.W.; Tweak to treat: Reprogramming bacteria for cancer treatment. Trends Cancer  2021,7(5),447-464","journal-title":"Trends Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2401538","DOI":"10.1002\/adhm.202401538","volume":"13","author":"Wang C.","year":"2024","unstructured":"Wang C.; Feng Q.; Shi S.; The rational engineered bacteria based biohybrid living system for tumor therapy. Adv Healthc Mater  2024,13(28),2401538","journal-title":"Adv Healthc Mater"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"114100","DOI":"10.1016\/j.colsurfb.2024.114100","volume":"242","author":"Wang C.","year":"2024","unstructured":"Wang C.; Wang B.; Zhang Q.; Zhang S.; Tumor microenvironment-responsive cell-penetrating peptides: Design principle and precision delivery. Colloids Surf B Biointerfaces  2024,242,114100","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/1162938","volume":"2022","author":"Karmacharya J.","year":"2022","unstructured":"Karmacharya J.; Shrestha P.; Han S.R.; Park H.; Oh T.J.; Complete genome sequencing of polar Arthrobacter sp. PAMC25284, copper tolerance potential unraveled with genomic analysis. Int J Microbiol  2022,2022,1-12","journal-title":"Int J Microbiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/oxfordjournals.jbchem.a126865","volume":"45","author":"Horio T.","year":"1958","unstructured":"Horio T.; Terminal oxidation system in bacteria. J Biochem  1958,45(4),267-279","journal-title":"J Biochem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1099\/00221287-146-10-2521","volume":"146","author":"Zaborina O.","year":"2000","unstructured":"Zaborina O.; Dhiman N.; Ling Chen M.; Kostal J.; Holder I.A.; Chakrabarty A.M.; Secreted products of a nonmucoid Pseudomonas aeruginosa strain induce two modes of macrophage killing: External-ATP-dependent, P2Z-receptor-mediated necrosis and ATP-independent, caspase-mediated apoptosis. Microbiology  2000,146(10),2521-2530","journal-title":"Microbiology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.4161\/cc.5.15.2992","volume":"5","author":"Chaudhari A.","year":"2006","unstructured":"Chaudhari A.; Fialho A.M.; Ratner D.; Azurin, Plasmodium falciparum malaria and HIV\/AIDS: Inhibition of parasitic and viral growth by Azurin. Cell Cycle  2006,5(15),1642-1648","journal-title":"Cell Cycle"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1021\/bi061661x","volume":"46","author":"Chaudhari A.","year":"2007","unstructured":"Chaudhari A.; Mahfouz M.; Fialho A.M.; Cupredoxin-cancer interrelationship: Azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry  2007,46(7),1799-1810","journal-title":"Biochemistry"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"103850","DOI":"10.1016\/j.ebiom.2022.103850","volume":"76","author":"Goto M.","year":"2022","unstructured":"Goto M.; Ryoo I.; Naffouje S.; Image-guided surgery with a new tumour-targeting probe improves the identification of positive margins. EBioMedicine  2022,76,103850","journal-title":"EBioMedicine"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"940001","DOI":"10.3389\/fonc.2022.940001","volume":"12","author":"Mander S.","year":"2022","unstructured":"Mander S.; Naffouje S.A.; Gao J.; Tumor-targeting cell-penetrating peptide, p28, for glioblastoma imaging and therapy. Front Oncol  2022,12,940001","journal-title":"Front Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/0008-5472.CAN-08-2932","volume":"69","author":"Taylor B.N.","year":"2009","unstructured":"Taylor B.N.; Mehta R.R.; Yamada T.; Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res  2009,69(2),537-546","journal-title":"Cancer Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/bjc.2013.266","volume":"108","author":"Yamada T.","year":"2013","unstructured":"Yamada T.; Christov K.; Shilkaitis A.; p28, A first in class peptide inhibitor of cop1 binding to p53. Br J Cancer  2013,108(12),2495-2504","journal-title":"Br J Cancer"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-15-2355","volume":"76","author":"Yamada T.","year":"2016","unstructured":"Yamada T.; Das Gupta T.K.; Beattie C.W.; p28-mediated activation of p53 in G2\u2013M phase of the cell cycle enhances the efficacy of DNA damaging and antimitotic chemotherapy. Cancer Res  2016,76(8),2354-2365","journal-title":"Cancer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/15384101.2016.1172147","volume":"15","author":"Bernardes N.","year":"2016","unstructured":"Bernardes N.; Abreu S.; Carvalho F.A.; Fernandes F.; Santos N.C.; Fialho A.M.; Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased \u03b21 integrin-mediated adhesion. Cell Cycle  2016,15(11),1415-1424","journal-title":"Cell Cycle"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1080\/15384101.2018.1489178","volume":"17","author":"Bernardes N.","year":"2018","unstructured":"Bernardes N.; Garizo A.R.; Pinto S.N.; Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs. Cell Cycle  2018,17(13),1649-1666","journal-title":"Cell Cycle"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"69023","DOI":"10.1371\/journal.pone.0069023","volume":"8","author":"Bernardes N.","year":"2013","unstructured":"Bernardes N.; Ribeiro A.S.; Abreu S.; The bacterial protein azurin impairs invasion and FAK\/Src signaling in P-cadherin-overexpressing breast cancer cell models. PLoS One  2013,8(7),69023","journal-title":"PLoS One"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biocel.2014.01.023","volume":"50","author":"Bernardes N.","year":"2014","unstructured":"Bernardes N.; Ribeiro A.S.; Abreu S.; High-throughput molecular profiling of a P-cadherin overexpressing breast cancer model reveals new targets for the anti-cancer bacterial protein azurin. Int J Biochem Cell Biol  2014,50,1-9","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2012\/642345","volume":"2012","author":"Fialho A.M.","year":"2012","unstructured":"Fialho A.M.; Salunkhe P.; Manna S.; Mahali S.; Chakrabarty A.M.; Glioblastoma multiforme: Novel therapeutic approaches. ISRN Neurol  2012,2012,1-10","journal-title":"ISRN Neurol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1080\/15384101.2016.1179034","volume":"15","author":"Chakrabarty A.M.","year":"2016","unstructured":"Chakrabarty A.M.; Bacterial azurin in potential cancer therapy. Cell Cycle  2016,15(13),1665-1666","journal-title":"Cell Cycle"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3934\/microbiol.2016.3.292","volume":"2","author":"Fialho A.","year":"2016","unstructured":"Fialho A.; Bernardes N.; Chakrabarty A.M.; Exploring the anticancer potential of the bacterial protein azurin. AIMS Microbiol  2016,2(3),292-303","journal-title":"AIMS Microbiol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1201\/9781351041904-9","volume":"319","author":"Garizo A.R.","year":"2019","unstructured":"Garizo A.R.; Bernardes N.; Chakrabarty A.M.; Fialho A.M.; The anticancer potential of the bacterial protein azurin and its derived peptide p28. Microb Infect Cancer Ther  2019,319,319-338","journal-title":"Microb Infect Cancer Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4103\/AIHB.AIHB_69_20","volume":"11","author":"Dharmawickreme R.B.L.","year":"2021","unstructured":"Dharmawickreme R.B.L.; Witharana C.; Bacterial protein azurin and tumour suppressor p53 in cancer regression. Adv Hum Biol  2021,11(2),147-151","journal-title":"Adv Hum Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/pro.3310","volume":"26","author":"Gao M.","year":"2017","unstructured":"Gao M.; Zhou J.; Su Z.; Huang Y.; Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein\u2013protein interactions and cancer therapy. Protein Sci  2017,26(12),2334-2341","journal-title":"Protein Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s10930-020-09891-3","volume":"39","author":"Huang F.","year":"2020","unstructured":"Huang F.; Shu Q.; Qin Z.; Anticancer actions of azurin and its derived peptide p28. Protein J  2020,39(2),182-189","journal-title":"Protein J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00384-020-03535-9","volume":"35","author":"Yaghoubi A.","year":"2020","unstructured":"Yaghoubi A.; Khazaei M.; Avan A.; Hasanian S.M.; Soleimanpour S.; The bacterial instrument as a promising therapy for colon cancer. Int J Colorectal Dis  2020,35(4),595-606","journal-title":"Int J Colorectal Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"20896","DOI":"10.1074\/jbc.M113.460162","volume":"288","author":"Cruz-Gallardo I.","year":"2013","unstructured":"Cruz-Gallardo I.; D\u00edaz-Moreno I.; D\u00edaz-Quintana A.; Antimalarial activity of cupredoxins: The interaction of Plasmodium merozoite surface protein 119 (MSP119) and rusticyanin. J Biol Chem  2013,288(29),20896-20907","journal-title":"J Biol Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1128\/AAC.01005-07","volume":"52","author":"Naguleswaran A.","year":"2008","unstructured":"Naguleswaran A.; Fialho A.M.; Chaudhari A.; Hong C.S.; Chakrabarty A.M.; Sullivan W.J.; Azurin-like protein blocks invasion of Toxoplasma gondii through potential interactions with parasite surface antigen SAG1. Antimicrob Agents Chemother  2008,52(2),402-408","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1080\/07391102.2020.1787864","volume":"39","author":"Sasidharan S.","year":"2021","unstructured":"Sasidharan S.; Selvaraj C.; Singh S.K.; Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: Insights from molecular docking and molecular dynamics simulations. J Biomol Struct Dyn  2021,39(15),5706-5721","journal-title":"J Biomol Struct Dyn"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3390\/pharmaceutics15071825","volume":"15","author":"Aslam S.","year":"2023","unstructured":"Aslam S.; Rehman H.M.; Sarwar M.Z.; Computational modeling, high-level soluble expression and in vitro cytotoxicity assessment of recombinant Pseudomonas aeruginosa azurin: A promising anti-cancer therapeutic candidate. Pharmaceutics  2023,15(7),1825","journal-title":"Pharmaceutics"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"106566","DOI":"10.1016\/j.pep.2024.106566","volume":"224","author":"Riegerov\u00e1 P.","year":"2024","unstructured":"Riegerov\u00e1 P.; Horv\u00e1th M.; \u0160ebesta F.; S\u00fdkora J.; \u0160ulc M.; Vl\u010dek A.; Single-step purification and characterization of Pseudomonas aeruginosa azurin. Protein Expr Purif  2024,224,106566","journal-title":"Protein Expr Purif"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1039\/D4AY00268G","volume":"16","author":"Bradley V.C.","year":"2024","unstructured":"Bradley V.C.; Manard B.T.; Hendriks L.; Quantifying platinum binding on protein-functionalized magnetic microparticles using single particle-ICP-TOF-MS. Anal Methods  2024,16(20),3192-3201","journal-title":"Anal Methods"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/molecules29020350","volume":"29","author":"Gibbs C.A.","year":"2024","unstructured":"Gibbs C.A.; Ghazi N.; Tao J.; Warren J.J.; An investigation of the influence of tyrosine local interactions on electron hopping in a model protein. Molecules  2024,29(2),350","journal-title":"Molecules"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2405156121","DOI":"10.1073\/pnas.2405156121","volume":"121","author":"Li P.","year":"2024","unstructured":"Li P.; Bera S.; Kumar-Saxena S.; Electron transport through two interacting channels in Azurin-based solid-state junctions. Proc Natl Acad Sci USA  2024,121(33),2405156121","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.3390\/ijms26094125","volume":"26","author":"Tuzhilkin R.","year":"2025","unstructured":"Tuzhilkin R.; Ondru\u0161ka V.; \u0160ulc M.; Azurin: A Model to Study a Metal Coordination Sphere or Electron Transfer in Metalloproteins. Int J Mol Sci  2025,26(9),4125","journal-title":"Int J Mol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1021\/acs.jpcb.3c07089","volume":"128","author":"Joy A.","year":"2024","unstructured":"Joy A.; Biswas R.; Significance of the disulfide bridge in the structure and stability of metalloprotein azurin. J Phys Chem B  2024,128(4),973-984","journal-title":"J Phys Chem B"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"112651","DOI":"10.1016\/j.jinorgbio.2024.112651","volume":"259","author":"Wei Y.","year":"2024","unstructured":"Wei Y.; Li P.; Theoretical insights into the reduction of Azurin metal site with unnatural amino acid substitutions. J Inorg Biochem  2024,259,112651","journal-title":"J Inorg Biochem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00894-024-06025-9","volume":"30","author":"Matsuura Y.","year":"2024","unstructured":"Matsuura Y.; Coherent spin transport in a copper protein. J Mol Model  2024,30(7),218","journal-title":"J Mol Model"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/genes13020301","volume":"13","author":"Virieux-Petit M.","year":"2022","unstructured":"Virieux-Petit M.; Hammer-Dedet F.; Aujoulat F.; Jumas-Bilak E.; Romano-Bertrand S.; From Copper Tolerance to Resistance in Pseudomonas aeruginosa towards Patho-Adaptation and Hospital Success. Genes  2022,13(2),301","journal-title":"Genes"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3389\/fcell.2020.00471","volume":"8","author":"Silva M.","year":"2020","unstructured":"Silva M.; Monteiro G.A.; Fialho A.M.; Bernardes N.; da Silva C.L.; Conditioned medium from azurin-expressing human mesenchymal stromal cells demonstrates antitumor activity against breast and lung cancer cell lines. Front Cell Dev Biol  2020,8,471","journal-title":"Front Cell Dev Biol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2016.12.003","volume":"4","author":"Mehta N.","year":"2017","unstructured":"Mehta N.; Lyon J.G.; Patil K.; Mokarram N.; Kim C.; Bellamkonda R.V.; Bacterial carriers for glioblastoma therapy. Mol Ther Oncolytics  2017,4,1-17","journal-title":"Mol Ther Oncolytics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"D313","DOI":"10.1093\/nar\/gkw1132","volume":"45","author":"Bienert S.","year":"2017","unstructured":"Bienert S.; Waterhouse A.; de Beer T.A.P.; The SWISS-MODEL repository \u2013 new features and functionality. Nucleic Acids Res  2017,45(D1),D313-D319","journal-title":"Nucleic Acids Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s42003-023-04458-1","volume":"6","author":"Hu J.","year":"2023","unstructured":"Hu J.; Jiang W.; Zuo J.; Structural basis of bacterial effector protein azurin targeting tumor suppressor p53 and inhibiting its ubiquitination. Commun Biol  2023,6(1),59","journal-title":"Commun Biol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"119908","DOI":"10.1016\/j.bbamcr.2025.119908","volume":"1872","author":"Saha G.","year":"2025","unstructured":"Saha G.; Ghosh M.K.; The key vulnerabilities and therapeutic opportunities in the USP7-p53\/MDM2 axis in cancer. Biochim Biophys Acta Mol Cell Res  2025,1872(3),119908","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/biomedicines9091194","volume":"9","author":"Garizo A.R.","year":"2021","unstructured":"Garizo A.R.; Coelho L.F.; Pinto S.; The azurin-derived peptide CT-p19LC exhibits membrane-active properties and induces cancer cell death. Biomedicines  2021,9(9),1194","journal-title":"Biomedicines"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/jmr.1105","volume":"24","author":"Domenici F.","year":"2011","unstructured":"Domenici F.; Frasconi M.; Mazzei F.; D\u2019Orazi G.; Bizzarri A.R.; Cannistraro S.; Azurin modulates the association of Mdm2 with p53: SPR evidence from interaction of the full-length proteins. J Mol Recognit  2011,24(4),707-714","journal-title":"J Mol Recognit"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1021\/acs.biochem.7b00085","volume":"56","author":"Chen R.","year":"2017","unstructured":"Chen R.; Zhou J.; Qin L.; A fusion protein of the p53 transactivation domain and the p53-binding domain of the oncoprotein MdmX as an efficient system for high-throughput screening of MdmX inhibitors. Biochemistry  2017,56(25),3273-3282","journal-title":"Biochemistry"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3389\/fonc.2020.01303","volume":"10","author":"Yaghoubi A.","year":"2020","unstructured":"Yaghoubi A.; Khazaei M.; Avan A.; Hasanian S.M.; Cho W.C.; Soleimanpour S.; p28 bacterial peptide, as an anticancer agent. Front Oncol  2020,10,1303","journal-title":"Front Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.bbagen.2018.11.003","volume":"1863","author":"Bizzarri A.R.","year":"2019","unstructured":"Bizzarri A.R.; Moscetti I.; Cannistraro S.; Interaction of the anticancer p28 peptide with p53-DBD as studied by fluorescence, FRET, docking and MD simulations. Biochim Biophys Acta, Gen Subj  2019,1863(2),342-350","journal-title":"Biochim Biophys Acta, Gen Subj"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/IJN.S152214","volume":"13","author":"Moscetti I.","year":"2018","unstructured":"Moscetti I.; Bizzarri A.R.; Cannistraro S.; Imaging and kinetics of the bimolecular complex formed by the tumor suppressor p53 with ubiquitin ligase COP1 as studied by atomic force microscopy and surface plasmon resonance. Int J Nanomedicine  2018,13,251-259","journal-title":"Int J Nanomedicine"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"148785","DOI":"10.1016\/j.gene.2024.148785","volume":"928","author":"Elazab I.M.","year":"2024","unstructured":"Elazab I.M.; El-Feky O.A.; Khedr E.G.; El-Ashmawy N.E.; Prostate cancer and the cell cycle: Focusing on the role of microRNAs. Gene  2024,928,148785","journal-title":"Gene"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/17425247.2022.2034784","volume":"29","author":"Chen Y.","year":"2023","unstructured":"Chen Y.; Zeng H.; Hou M.; Qiu Y.; Azurin regulates p21 and enhances the sensitivity of osteosarcoma cells to cisplatin. Altern Ther Health Med  2023,29(7),119-125","journal-title":"Altern Ther Health Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/PPO.0000000000000714","volume":"30","author":"Nasri E.","year":"2024","unstructured":"Nasri E.; Torrence D.E.; Vasilopoulos T.; Cell cycle checkpoints p16 and p21-strong predictors of clinicopathologic outcomes in high-grade osteosarcoma. Cancer J  2024,30(3),133-139","journal-title":"Cancer J"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10989-011-9265-9","volume":"17","author":"Micewicz E.D.","year":"2011","unstructured":"Micewicz E.D.; Jung C.L.; Schaue D.; Luong H.; McBride W.H.; Ruchala P.; Small azurin-derived peptide targets ephrin receptors for radiotherapy. Int J Pept Res Ther  2011,17(3),247-257","journal-title":"Int J Pept Res Ther"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","volume":"24","author":"Pasquale E.B.","year":"2024","unstructured":"Pasquale E.B.; Eph receptors and ephrins in cancer progression. Nat Rev Cancer  2024,24(1),5-27","journal-title":"Nat Rev Cancer"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1021\/acs.molpharmaceut.3c00387","volume":"20","author":"Bhardwaj R.","year":"2023","unstructured":"Bhardwaj R.; Mishra P.; Engineered recombinant EGFP-azurin theranostic nanosystem for targeted therapy of prostate cancer. Mol Pharm  2023,20(12),6066-6078","journal-title":"Mol Pharm"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"571237","DOI":"10.3389\/fcell.2020.571237","volume":"8","author":"Preta G.","year":"2020","unstructured":"Preta G.; New insights into targeting membrane lipids for cancer therapy. Front Cell Dev Biol  2020,8,571237","journal-title":"Front Cell Dev Biol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"70017","DOI":"10.1002\/jex2.70017","volume":"3","author":"Jackson Cullison S.R.","year":"2024","unstructured":"Jackson Cullison S.R.; Flemming J.P.; Karagoz K.; Wermuth P.J.; Mahoney M.G.; Mechanisms of extracellular vesicle uptake and implications for the design of cancer therapeutics. J Extracell Biol  2024,3(11),70017","journal-title":"J Extracell Biol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/cancers16152754","volume":"16","author":"Eshaq A.M.","year":"2024","unstructured":"Eshaq A.M.; Flanagan T.W.; Hassan S.Y.; Non-receptor tyrosine kinases: Their structure and mechanistic role in tumor progression and resistance. Cancers  2024,16(15),2754","journal-title":"Cancers"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"230031","DOI":"10.1530\/ERC-23-0031","volume":"30","author":"Galifi C.A.","year":"2023","unstructured":"Galifi C.A.; Wood T.L.; Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: Sticking points in understanding IGF1R function in cancer. Endocr Relat Cancer  2023,30(10),230031","journal-title":"Endocr Relat Cancer"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jmr.861","volume":"21","author":"Stevens F.J.","year":"2008","unstructured":"Stevens F.J.; Homology versus analogy: Possible evolutionary relationship of immunoglobulins, cupredoxins, and Cu,Zn-superoxide dismutase. J Mol Recognit  2008,21(1),20-29","journal-title":"J Mol Recognit"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.37349\/etat.2024.00264","volume":"5","author":"Sood A.","year":"2024","unstructured":"Sood A.; Jothiswaran V.V.; Singh A.; Sharma A.; Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment. Explorat Targeted Anti-tumor Therapy  2024,5(5),1074-1099","journal-title":"Explorat Targeted Anti-tumor Therapy"},{"key":"ref=71","first-page":"245","volume":"42","author":"Hassan L.A.","year":"2023","unstructured":"Hassan L.A.; Darweesh M.F.; Hasan T.H.; The immune-modulator activity of pseudomonas aeruginosa extracted protein: Azurin charming protein. Lat Am J Pharm  2023,42(S),245-251","journal-title":"Lat Am J Pharm"},{"key":"ref=72","first-page":"1630","volume":"43","author":"Hassan L.A.","year":"2024","unstructured":"Hassan L.A.; Darweesh M.F.; Al-Muhanna S.G.; Evaluation the fascinating effect of redox protein on the immune system. Lat Am J Pharm  2024,43(S5),1630-1636","journal-title":"Lat Am J Pharm"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.34172\/jsums.2020.07","volume":"22","author":"Ghasemi-Dehkordi P.","year":"2020","unstructured":"Ghasemi-Dehkordi P.; Doosti A.; Jami M.S.; The effects of pBudCE4.1-azurin-MAM-A recombinant vector on IL-2, IL-6, IL-7, and IL-10 expressions in laboratory mice. Shahrekord Univ Med Sci J  2020,22(1),38-45","journal-title":"Shahrekord Univ Med Sci J"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"768","DOI":"10.22038\/IJBMS.2023.68331.14913","volume":"26","author":"Yaghoubi A.","year":"2023","unstructured":"Yaghoubi A.; Movaqar A.; Asgharzadeh F.; Anticancer activity of Pseudomonas aeruginosa derived peptide with iRGD in colon cancer therapy. Iran J Basic Med Sci  2023,26(7),768-776","journal-title":"Iran J Basic Med Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10753-021-01615-8","volume":"45","author":"Man M.Q.","year":"2022","unstructured":"Man M.Q.; Wakefield J.S.; Mauro T.M.; Elias P.M.; Regulatory role of nitric oxide in cutaneous inflammation. Inflammation  2022,45(3),949-964","journal-title":"Inflammation"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"9795","DOI":"10.1039\/D4TB00741G","volume":"12","author":"Qin S.","year":"2024","unstructured":"Qin S.; He G.; Yang J.; Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy. J Mater Chem B Mater Biol Med  2024,12(39),9795-9820","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12866-021-02274-3","volume":"21","author":"Ebrahimzadeh S.","year":"2021","unstructured":"Ebrahimzadeh S.; Ahangari H.; Soleimanian A.; Colorectal cancer treatment using bacteria: Focus on molecular mechanisms. BMC Microbiol  2021,21(1),218","journal-title":"BMC Microbiol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41417-023-00715-x","volume":"31","author":"Giurini E.F.","year":"2024","unstructured":"Giurini E.F.; Godla A.; Gupta K.H.; Redefining bioactive small molecules from microbial metabolites as revolutionary anticancer agents. Cancer Gene Ther  2024,31(2),187-206","journal-title":"Cancer Gene Ther"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/biom11081120","volume":"11","author":"Bakare O.O.","year":"2021","unstructured":"Bakare O.O.; Gokul A.; Wu R.; Niekerk L.A.; Klein A.; Keyster M.; Biomedical relevance of novel anticancer peptides in the sensitive treatment of cancer. Biomolecules  2021,11(8),1120","journal-title":"Biomolecules"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"851140","DOI":"10.3389\/fcimb.2022.851140","volume":"12","year":"2022","unstructured":"Anjana, Tiwari SK. Bacteriocin-producing probiotic lactic acid bacteria in controlling dysbiosis of the gut microbiota. Front Cell Infect Microbiol  2022,12,851140","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"110152","DOI":"10.1016\/j.cbi.2022.110152","volume":"366","author":"Balcik-Ercin P.","year":"2022","unstructured":"Balcik-Ercin P.; Sever B.; An investigation of bacteriocin nisin anti-cancer effects and FZD7 protein interactions in liver cancer cells. Chem Biol Interact  2022,366,110152","journal-title":"Chem Biol Interact"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"128325","DOI":"10.1016\/j.ijbiomac.2023.128325","volume":"256","author":"Daba G.M.","year":"2024","unstructured":"Daba G.M.; Elkhateeb W.A.; Ribosomally synthesized bacteriocins of lactic acid bacteria: Simplicity yet having wide potentials \u2013 A review. Int J Biol Macromol  2024,256(Pt 1),128325","journal-title":"Int J Biol Macromol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10989-022-10386-1","volume":"28","author":"Goh K.S.","year":"2022","unstructured":"Goh K.S.; Ng Z.J.; Halim M.; Oslan S.N.; Oslan S.N.H.; Tan J.S.; A comprehensive review on the anticancer potential of bacteriocin: Preclinical and clinical studies. Int J Pept Res Ther  2022,28(2),75","journal-title":"Int J Pept Res Ther"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"D403","DOI":"10.1093\/nar\/gkae1046","volume":"53","author":"Ma T.","year":"2025","unstructured":"Ma T.; Liu Y.; Yu B.; DRAMP 4.0: An open-access data repository dedicated to the clinical translation of antimicrobial peptides. Nucleic Acids Res  2025,53(D1),D403-D410","journal-title":"Nucleic Acids Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2024.01.010","volume":"176","author":"Liu Z.","year":"2024","unstructured":"Liu Z.; Liu X.; Zhang W.; Gao R.; Wei H.; Yu C.Y.; Current advances in modulating tumor hypoxia for enhanced therapeutic efficacy. Acta Biomater  2024,176,1-27","journal-title":"Acta Biomater"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12951-022-01373-1","volume":"20","author":"Xiao S.","year":"2022","unstructured":"Xiao S.; Shi H.; Zhang Y.; Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer. J Nanobiotechnology  2022,20(1),178","journal-title":"J Nanobiotechnology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/microorganisms10010009","volume":"10","author":"Gammuto L.","year":"2021","unstructured":"Gammuto L.; Chiellini C.; Iozzo M.; Fani R.; Petroni G.; The azurin coding gene: Origin and phylogenetic distribution. Microorganisms  2021,10(1),9","journal-title":"Microorganisms"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"305","DOI":"10.31083\/j.fbl2711305","volume":"27","author":"Iozzo M.","year":"2022","unstructured":"Iozzo M.; Vitali F.; Chiellini C.; Preliminary analysis of the presence of bacterial azurin coding gene in CRC patients and correlation with the microbiota composition. Front Biosci Land  2022,27(11),305","journal-title":"Front Biosci Land"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"101513","DOI":"10.1016\/j.xcrm.2024.101513","volume":"5","author":"Gao T.","year":"2024","unstructured":"Gao T.; Niu L.; Wu X.; Sonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models. Cell Rep Med  2024,5(5),101513","journal-title":"Cell Rep Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2313389","DOI":"10.1002\/adma.202313389","volume":"36","author":"Jia J.","year":"2024","unstructured":"Jia J.; Wang X.; Lin X.; Zhao Y.; Engineered microorganisms for advancing tumor therapy. Adv Mater  2024,36(24),2313389","journal-title":"Adv Mater"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bioactmat.2023.09.007","volume":"32","author":"Lin Z.","year":"2024","unstructured":"Lin Z.; Meng F.; Ma Y.; In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity. Bioact Mater  2024,32,12-27","journal-title":"Bioact Mater"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"122734","DOI":"10.1016\/j.lfs.2024.122734","volume":"349","author":"Kiaheyrati N.","year":"2024","unstructured":"Kiaheyrati N.; Babaei A.; Ranji R.; Bahadoran E.; Taheri S.; Farokhpour Z.; Cancer therapy with the viral and bacterial pathogens: The past enemies can be considered the present allies. Life Sci  2024,349,122734","journal-title":"Life Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"108336","DOI":"10.1016\/j.biotechadv.2024.108336","volume":"72","author":"Murali S.K.","year":"2024","unstructured":"Murali S.K.; Mansell T.J.; Next generation probiotics: Engineering live biotherapeutics. Biotechnol Adv  2024,72,108336","journal-title":"Biotechnol Adv"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2313953","DOI":"10.1002\/adma.202313953","volume":"36","author":"Zhou Y.","year":"2024","unstructured":"Zhou Y.; Li Q.; Wu Y.; Synergistic brilliance: Engineered bacteria and nanomedicine unite in cancer therapy. Adv Mater  2024,36(21),2313953","journal-title":"Adv Mater"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/1751-7915.13523","volume":"13","author":"Yu X.","year":"2020","unstructured":"Yu X.; Lin C.; Yu J.; Qi Q.; Wang Q.; Bioengineered Escherichia coli Nissle 1917 for tumour-targeting therapy. Microb Biotechnol  2020,13(3),629-636","journal-title":"Microb Biotechnol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"111935","DOI":"10.1016\/j.intimp.2024.111935","volume":"132","author":"Xia X.","year":"2024","unstructured":"Xia X.; Zhang J.; Zhao B.; Progress of engineered bacteria for tumour therapy. Int Immunopharmacol  2024,132,111935","journal-title":"Int Immunopharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1038\/s41467-022-31932-x","volume":"13","author":"Chen Y.","year":"2022","unstructured":"Chen Y.; Du M.; Yuan Z.; Chen Z.; Yan F.; Spatiotemporal control of engineered bacteria to express interferon-\u03b3 by focused ultrasound for tumor immunotherapy. Nat Commun  2022,13(1),4468","journal-title":"Nat Commun"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/microorganisms13010075","volume":"13","author":"Jia L.","year":"2025","unstructured":"Jia L.; Zhu L.; The bacterial type III secretion system as a broadly applied protein delivery tool in biological sciences. Microorganisms  2025,13(1),75","journal-title":"Microorganisms"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"eabd7614","DOI":"10.1126\/sciadv.abd7614","volume":"7","author":"Lv Y.","year":"2021","unstructured":"Lv Y.; Li F.; Wang S.; Near-infrared light\u2013triggered platelet arsenal for combined photothermal-immunotherapy against cancer. Sci Adv  2021,7(13),eabd7614","journal-title":"Sci Adv"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"7603","DOI":"10.1128\/AEM.01390-12","volume":"78","author":"Zhang Y.","year":"2012","unstructured":"Zhang Y.; Zhang Y.; Xia L.; Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl Environ Microbiol  2012,78(21),7603-7610","journal-title":"Appl Environ Microbiol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/bioengineering10101188","volume":"10","author":"Ma Y.","year":"2023","unstructured":"Ma Y.; Zhu G.; Feng L.; Jiang S.; Xiang Q.; Wang J.; Efficient cytotoxicity of recombinant Azurin in Escherichia coli nissle 1917-derived minicells against colon cancer cells. Bioengineering  2023,10(10),1188","journal-title":"Bioengineering"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"27","DOI":"10.32604\/or.2024.056955","volume":"33","author":"Abdessalem M.A.","year":"2025","unstructured":"Abdessalem M.A.; Adham S.A.; Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells. Oncol Res  2025,33(1),27-44","journal-title":"Oncol Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11523-024-01051-2","volume":"19","author":"Evans L.","year":"2024","unstructured":"Evans L.; Walker R.; MacDiarmid J.; A phase 1 study of intravenous EGFR-ErbituxEDVsMIT in children with solid or CNS tumours expressing epidermal growth factor receptor. Target Oncol  2024,19(3),333-342","journal-title":"Target Oncol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.3390\/cancers16172971","volume":"16","author":"Radford G.A.","year":"2024","unstructured":"Radford G.A.; Vrbanac L.; de Nys R.T.; Towards understanding tumour colonisation by probiotic bacterium E. coli nissle 1917. Cancers  2024,16(17),2971","journal-title":"Cancers"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"174593","DOI":"10.1016\/j.ejphar.2021.174593","volume":"916","author":"Ghasemi K.","year":"2022","unstructured":"Ghasemi K.; Ghasemi K.; A Brief look at antitumor effects of doxycycline in the treatment of colorectal cancer and combination therapies. Eur J Pharmacol  2022,916,174593","journal-title":"Eur J Pharmacol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"121709","DOI":"10.1016\/j.lfs.2023.121709","volume":"324","author":"Tang H.","year":"2023","unstructured":"Tang H.; Zhou T.; Jin W.; Tumor-targeting engineered probiotic Escherichia coli Nissle 1917 inhibits colorectal tumorigenesis and modulates gut microbiota homeostasis in mice. Life Sci  2023,324,121709","journal-title":"Life Sci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1447176","DOI":"10.3389\/fbioe.2024.1447176","volume":"12","author":"Van den Berghe L.","year":"2024","unstructured":"Van den Berghe L.; Masschelein J.; Pinheiro V.B.; From competition to cure: The development of live biotherapeutic products for anticancer therapy in the iGEM competition. Front Bioeng Biotechnol  2024,12,1447176","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"2397874","DOI":"10.1080\/19490976.2024.2397874","volume":"16","author":"Falzone L.","year":"2024","unstructured":"Falzone L.; Lavoro A.; Candido S.; Salmeri M.; Zangh\u00ec A.; Libra M.; Benefits and concerns of probiotics: An overview of the potential genotoxicity of the colibactin-producing Escherichia coli Nissle 1917 strain. Gut Microbes  2024,16(1),2397874","journal-title":"Gut Microbes"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1321386","DOI":"10.3389\/fmicb.2023.1321386","volume":"14","author":"Qu B.","year":"2024","unstructured":"Qu B.; Yuan J.; Liu X.; Zhang S.; Ma X.; Lu L.; Anticancer activities of natural antimicrobial peptides from animals. Front Microbiol  2024,14,1321386","journal-title":"Front Microbiol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"114996","DOI":"10.1016\/j.biopha.2023.114996","volume":"164","author":"Chinnadurai R.K.","year":"2023","unstructured":"Chinnadurai R.K.; Khan N.; Meghwanshi G.K.; Ponne S.; Althobiti M.; Kumar R.; Current research status of anti-cancer peptides: Mechanism of action, production, and clinical applications. Biomed Pharmacother  2023,164,114996","journal-title":"Biomed Pharmacother"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1021\/acs.jcim.4c00295","volume":"64","author":"Bhattarai S.","year":"2024","unstructured":"Bhattarai S.; Tayara H.; Chong K.T.; Advancing peptide-based cancer therapy with AI: In-depth analysis of state-of-the-art AI models. J Chem Inf Model  2024,64(13),4941-4957","journal-title":"J Chem Inf Model"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/pharmaceutics17010046","volume":"17","author":"Lei Y.","year":"2025","unstructured":"Lei Y.; Liu J.; Bai Y.; Zheng C.; Wang D.; Peptides as versatile regulators in cancer immunotherapy: Recent advances, challenges, and future prospects. Pharmaceutics  2025,17(1),46","journal-title":"Pharmaceutics"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","volume":"55","author":"Vadevoo S.M.P.","year":"2023","unstructured":"Vadevoo S.M.P.; Gurung S.; Lee H.S.; Peptides as multifunctional players in cancer therapy. Exp Mol Med  2023,55(6),1099-1109","journal-title":"Exp Mol Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3390\/molecules28031148","volume":"28","author":"Ghaly G.","year":"2023","unstructured":"Ghaly G.; Tallima H.; Dabbish E.; Anti-cancer peptides: Status and future prospects. Molecules  2023,28(3),1148","journal-title":"Molecules"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/polym14030594","volume":"14","author":"Khazaei Monfared Y.","year":"2022","unstructured":"Khazaei Monfared Y.; Mahmoudian M.; Cecone C.; Stabilization and anticancer enhancing activity of the peptide nisin by cyclodextrin-based nanosponges against colon and breast cancer cells. Polymers  2022,14(3),594","journal-title":"Polymers"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ncomms1459","volume":"2","author":"L\u00e4ttig-T\u00fcnnemann G.","year":"2011","unstructured":"L\u00e4ttig-T\u00fcnnemann G.; Prinz M.; Hoffmann D.; Backbone rigidity and static presentation of guanidinium groups increases cellular uptake of arginine-rich cell-penetrating peptides. Nat Commun  2011,2(1),453","journal-title":"Nat Commun"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jconrel.2012.07.022","volume":"162","author":"Ma Y.","year":"2012","unstructured":"Ma Y.; Gong C.; Ma Y.; Direct cytosolic delivery of cargoes in vivo by a chimera consisting of D- and L-arginine residues. J Control Release  2012,162(2),286-294","journal-title":"J Control Release"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.3390\/cancers14225546","volume":"14","author":"Bottens R.A.","year":"2022","unstructured":"Bottens R.A.; Yamada T.; Cell-penetrating peptides (CPPs) as therapeutic and diagnostic agents for cancer. Cancers  2022,14(22),5546","journal-title":"Cancers"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.23812\/j.biol.regul.homeost.agents.20243807.448","volume":"38","author":"Shuaib H.","year":"2024","unstructured":"Shuaib H.; Saleem M.Z.; Alshahrani M.Y.; Development and bioactivity assessment of a recombinant Pseudomonas aeruginosa azurin-BR2 peptide fusion protein: A novel approach to cancer immunotherapy. J Biol Regul Homeost Agents  2024,38(7),5573-5581","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10989-022-10384-3","volume":"28","author":"Sadeghi F.","year":"2022","unstructured":"Sadeghi F.; Kajbaf M.; Shafiee F.; BR2, a buforin-derived cancer-specific cell-penetrating peptide for targeted delivering of toxic agents: A review article. Int J Pept Res Ther  2022,28(3),93","journal-title":"Int J Pept Res Ther"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"tfae179","DOI":"10.1093\/toxres\/tfae179","volume":"13","author":"Rehman H.M.","year":"2024","unstructured":"Rehman H.M.; Yousaf N.; Hina S.M.; Design and computational analysis of a novel Azurin-BR2 chimeric protein against breast cancer. Toxicol Res  2024,13(6),tfae179","journal-title":"Toxicol Res"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"670324","DOI":"10.3389\/fimmu.2021.670324","volume":"12","author":"Wang W.","year":"2021","unstructured":"Wang W.; Zou R.; Qiu Y.; Interaction networks converging on immunosuppressive roles of granzyme B: Special niches within the tumor microenvironment. Front Immunol  2021,12,670324","journal-title":"Front Immunol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s11033-019-04767-x","volume":"46","author":"Paydarnia N.","year":"2019","unstructured":"Paydarnia N.; Khoshtinat Nikkhoi S.; Fakhravar A.; Mehdiabdol M.; Heydarzadeh H.; Ranjbar S.; Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells. Mol Biol Rep  2019,46(3),3129-3140","journal-title":"Mol Biol Rep"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.3390\/cancers16223768","volume":"16","author":"Nikitovic D.","year":"2024","unstructured":"Nikitovic D.; Kukovyakina E.; Berdiaki A.; Enhancing tumor-targeted therapy: The role of iRGD peptide in advanced drug delivery systems. Cancers  2024,16(22),3768","journal-title":"Cancers"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"107598","DOI":"10.1016\/j.intimp.2021.107598","volume":"101","author":"Singh S.","year":"2021","unstructured":"Singh S.; Anshita D.; Ravichandiran V.; MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol  2021,101(Pt B),107598","journal-title":"Int Immunopharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"166703","DOI":"10.1016\/j.jmb.2020.11.002","volume":"433","author":"Kardani K.","year":"2021","unstructured":"Kardani K.; Bolhassani A.; Cppsite 2.0: An available database of experimentally validated cell-penetrating peptides predicting their secondary and tertiary structures. J Mol Biol  2021,433(11),166703","journal-title":"J Mol Biol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17425247.2022.2034784","volume":"19","author":"Cerrato C.P.","year":"2022","unstructured":"Cerrato C.P.; Langel \u00dc.; An update on cell-penetrating peptides with intracellular organelle targeting. Expert Opin Drug Deliv  2022,19(2),133-146","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.toxicon.2019.12.159","volume":"175","author":"Sousa M.L.","year":"2020","unstructured":"Sousa M.L.; Ribeiro T.; Vasconcelos V.; Linder S.; Urbatzka R.; Portoamides A and B are mitochondrial toxins and induce cytotoxicity on the proliferative cell layer of in vitro microtumours. Toxicon  2020,175,49-56","journal-title":"Toxicon"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"121127","DOI":"10.1016\/j.talanta.2020.121127","volume":"218","author":"Su P.","year":"2020","unstructured":"Su P.; Zhu Z.; Tian Y.; A TAT peptide-based ratiometric two-photon fluorescent probe for detecting biothiols and sequentially distinguishing GSH in mitochondria. Talanta  2020,218,121127","journal-title":"Talanta"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1038\/s41467-021-23997-x","volume":"12","author":"Teo S.L.Y.","year":"2021","unstructured":"Teo S.L.Y.; Rennick J.J.; Yuen D.; Al-Wassiti H.; Johnston A.P.R.; Pouton C.W.; Unravelling cytosolic delivery of cell penetrating peptides with a quantitative endosomal escape assay. Nat Commun  2021,12(1),3721","journal-title":"Nat Commun"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.2174\/0109298673278936240107121907","volume":"32","author":"Soni S.","year":"2025","unstructured":"Soni S.; Kori S.K.; Nema P.; Iyer A.K.; Soni V.; Kashaw S.K.; Cell-penetrating peptides as keys to endosomal escape and intracellular trafficking in nanomedicine delivery. Curr Med Chem  2025,32(7),1288-1312","journal-title":"Curr Med Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.3390\/ijms25116219","volume":"25","author":"Milewska S.","year":"2024","unstructured":"Milewska S.; Sadowska A.; Stefaniuk N.; Tumor-Homing peptides as crucial components of magnetic-based delivery systems: Recent developments and pharmacoeconomical perspective. Int J Mol Sci  2024,25(11),6219","journal-title":"Int J Mol Sci"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"tfae174","DOI":"10.1093\/toxres\/tfae174","volume":"13","author":"Khalid S.","year":"2024","unstructured":"Khalid S.; Rehman H.M.; Al-Qassab Y.; Design and computational analysis of a novel Leptulipin-p28 fusion protein as a multitarget anticancer therapy in breast cancer. Toxicol Res  2024,13(5),tfae174","journal-title":"Toxicol Res"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"735","DOI":"10.22037\/ijpr.2019.2392","volume":"18","author":"Soleimani M.","year":"2019","unstructured":"Soleimani M.; Mirmohammmad Sadeghi H.; Jahanian-Najafabadi A.; A bi-functional targeted P28-NRC chimeric protein with enhanced cytotoxic effects on breast cancer cell lines. Iran J Pharm Res  2019,18(2),735-744","journal-title":"Iran J Pharm Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1021\/acs.biomac.0c01216","volume":"21","author":"Raber H.F.","year":"2020","unstructured":"Raber H.F.; Heerde T.; El Din S.N.; Azulitox\u2014A Pseudomonas aeruginosa P28-derived cancer-cell-specific protein photosensitizer. Biomacromolecules  2020,21(12),5067-5076","journal-title":"Biomacromolecules"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/0113895575320468240912093945","volume":"25","author":"Ali N.","year":"2025","unstructured":"Ali N.; Rasheed L.; Rehman W.; A review on recent trends in photo-drug efficiency of advanced biomaterials in photodynamic therapy of cancer. Mini Rev Med Chem  2025,25(4),259-276","journal-title":"Mini Rev Med Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-981-15-8763-4_16","volume":"1293","author":"Riani Y.D.","year":"2021","unstructured":"Riani Y.D.; Matsuda T.; Nagai T.; Genetically encoded photosensitizer for destruction of protein or cell function. Adv Exp Med Biol  2021,1293,265-279","journal-title":"Adv Exp Med Biol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jbiotec.2021.08.014","volume":"341","author":"Favella P.","year":"2021","unstructured":"Favella P.; Kissmann A.K.; Raber H.F.; Diffusion-controlled release of the theranostic protein-photosensitizer Azulitox from composite of Fmoc-Phenylalanine Fibrils encapsulated with BSA hydrogels. J Biotechnol  2021,341,51-62","journal-title":"J Biotechnol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1002\/psc.3544","volume":"30","author":"Pierri G.","year":"2024","unstructured":"Pierri G.; Schettini R.; Advances in MRI: Peptide and peptidomimetic-based contrast agents. J Pept Sci  2024,30(3),3544","journal-title":"J Pept Sci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2967\/jnumed.120.251173","volume":"62","author":"Veal M.","year":"2021","unstructured":"Veal M.; Dias G.; Kersemans V.; Sneddon D.; Faulkner S.; Cornelissen B.; A model system to explore the detection limits of antibody-based immuno-SPECT imaging of exclusively intranuclear epitopes. J Nucl Med  2021,62(11),1537-1544","journal-title":"J Nucl Med"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"2311548","DOI":"10.1002\/adma.202311548","volume":"36","author":"Duan X.","year":"2024","unstructured":"Duan X.; Wang P.; He L.; Peptide-functionalized inorganic oxide nanomaterials for solid cancer imaging and therapy. Adv Mater  2024,36(37),2311548","journal-title":"Adv Mater"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/pharmaceutics13060890","volume":"13","author":"Stiltner J.","year":"2021","unstructured":"Stiltner J.; McCandless K.; Zahid M.; Cell-penetrating peptides: Applications in tumor diagnosis and therapeutics. Pharmaceutics  2021,13(6),890","journal-title":"Pharmaceutics"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s10895-023-03434-6","volume":"34","author":"Karmarkar R.","year":"2024","unstructured":"Karmarkar R.; Benjafield A.; Aroori S.; The role of colour segmented fluorescence (CSF) mode and same-day administration of low-dose indocyanine green in liver surgery: Our initial experience. J Fluoresc  2024,34(5),2133-2138","journal-title":"J Fluoresc"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/978-1-0716-1811-0_45","volume":"2394","author":"Naffouje S.","year":"2022","unstructured":"Naffouje S.; Goto M.; Ryoo I.; Green A.; Das Gupta T.K.; Yamada T.; A method of tumor in vivo imaging with a new peptide-based fluorescent probe. Methods Mol Biol  2022,2394,857-865","journal-title":"Methods Mol Biol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.1021\/acs.jmedchem.2c00417","volume":"65","author":"Naffouje S.A.","year":"2022","unstructured":"Naffouje S.A.; Goto M.; Coward L.U.; Nontoxic tumor-targeting optical agents for intraoperative breast tumor imaging. J Med Chem  2022,65(10),7371-7379","journal-title":"J Med Chem"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s12029-021-00654-6","volume":"53","author":"Al-Hazmi N.E.","year":"2022","unstructured":"Al-Hazmi N.E.; Naguib D.M.; Microbial azurin immobilized on nano-chitosan as anticancer and antibacterial agent against gastrointestinal cancers and related bacteria. J Gastrointest Cancer  2022,53(3),537-542","journal-title":"J Gastrointest Cancer"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24294\/can.v6i1.2306","volume":"6","author":"Bahramifar S.","year":"2023","unstructured":"Bahramifar S.; Baharifar H.; Maghami P.; Enhancement of anticancer effect of azurin using polymeric nanoparticles. Charact Applicat Nanomat  2023,6(1),1-9","journal-title":"Charact Applicat Nanomat"},{"key":"ref=148","first-page":"3ElQG6y","volume":"22","author":"Rani P.S.","year":"2025","unstructured":"Rani P.S.; Reddy S.A.; Anusha K.; An overview on tyrosine kinase inhibitor gefitinib drug delivery systems for enhanced treatment of cancer. Biotech Res Asia  2025,22(1),3ElQG6y","journal-title":"Biotech Res Asia"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jconrel.2021.07.035","volume":"337","author":"Garizo A.R.","year":"2021","unstructured":"Garizo A.R.; Castro F.; Martins C.; p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer. J Control Release  2021,337,329-342","journal-title":"J Control Release"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/0115734099299174240522115944","volume":"21","author":"Wang S.","year":"2025","unstructured":"Wang S.; Han J.; Wang Z.; Targeted therapy of tumors and cancer stem cells based on oxidant-regulated redox pathway and its mechanism. Curr Computeraided Drug Des  2025,21(4),425-440","journal-title":"Curr Computeraided Drug Des"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"102237","DOI":"10.1016\/j.cbpa.2022.102237","volume":"72","author":"Northcote-Smith J.","year":"2023","unstructured":"Northcote-Smith J.; Suntharalingam K.; Targeting chemotherapy-resistant tumour sub-populations using inorganic chemistry: Anti-cancer stem cell metal complexes. Curr Opin Chem Biol  2023,72,102237","journal-title":"Curr Opin Chem Biol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"4875578","DOI":"10.2139\/ssrn.4875578","author":"Sivakrishna N.","year":"2024","unstructured":"Sivakrishna N.; Kondaiah P.; Nethaji M.; Phenanthroline arbitrated potent anticancer activity of the copper complex of nucleobase derivatives. SSRN  2024,4875578","journal-title":"SSRN"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"2002246","DOI":"10.1002\/adma.202002246","volume":"32","author":"Lu X.","year":"2020","unstructured":"Lu X.; Gao S.; Lin H.; Bioinspired copper single-atom catalysts for tumor parallel catalytic therapy. Adv Mater  2020,32(36),2002246","journal-title":"Adv Mater"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1039\/D2DT00788F","volume":"51","author":"Johnson A.","year":"2022","unstructured":"Johnson A.; Iffland-M\u00fchlhaus L.; Northcote-Smith J.; A bioinspired redox-modulating copper(ii)\u2013macrocyclic complex bearing non-steroidal anti-inflammatory drugs with anti-cancer stem cell activity. Dalton Trans  2022,51(15),5904-5912","journal-title":"Dalton Trans"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/cancers15112975","volume":"15","author":"Merola E.","year":"2023","unstructured":"Merola E.; Grana C.M.; Peptide receptor radionuclide therapy (PRRT): Innovations and improvements. Cancers  2023,15(11),2975","journal-title":"Cancers"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/pharmaceutics15030971","volume":"15","author":"Chakraborty K.","year":"2023","unstructured":"Chakraborty K.; Mondal J.; An J.M.; Park J.; Lee Y.K.; Advances in radionuclides and radiolabeled peptides for cancer therapeutics. Pharmaceutics  2023,15(3),971","journal-title":"Pharmaceutics"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2967\/jnumed.120.258392","volume":"62","author":"Carlsen E.A.","year":"2021","unstructured":"Carlsen E.A.; Johnbeck C.B.; Loft M.; Semiautomatic tumor delineation for evaluation of 64Cu-DOTATATE PET\/CT in patients with neuroendocrine neoplasms: Prognostication based on lowest lesion uptake and total tumor volume. J Nucl Med  2021,62(11),1564-1570","journal-title":"J Nucl Med"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1039\/C3MT00357D","volume":"6","author":"Pinato O.","year":"2014","unstructured":"Pinato O.; Musetti C.; Sissi C.; Pt-based drugs: The spotlight will be on proteins. Metallomics  2014,6(3),380-395","journal-title":"Metallomics"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/GMO.1000111","volume":"1","year":"2017","unstructured":"A Ali M, S Mohamed M, G Sedek R, Anwar M. Can metal replacement increase the antitumor activity of azurin? (in vitro study). General Medicine Open  2017,1(2),1-7","journal-title":"General Medicine Open"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"22095","DOI":"10.1016\/j.heliyon.2023.e22095","volume":"10","author":"Mahgoub E.O.","year":"2024","unstructured":"Mahgoub E.O.; Cho W.C.; Sharifi M.; Role of functional genomics in identifying cancer drug resistance and overcoming cancer relapse. Heliyon  2024,10(1),22095","journal-title":"Heliyon"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/vaccines12010071","volume":"12","author":"Kozak M.","year":"2024","unstructured":"Kozak M.; Hu J.; DNA vaccines: Their formulations, engineering and delivery. Vaccines  2024,12(1),71","journal-title":"Vaccines"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1332939","DOI":"10.3389\/fimmu.2024.1332939","volume":"15","author":"Lu B.","year":"2024","unstructured":"Lu B.; Lim J.M.; Yu B.; The next-generation DNA vaccine platforms and delivery systems: Advances, challenges and prospects. Front Immunol  2024,15,1332939","journal-title":"Front Immunol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s12033-023-00798-9","volume":"66","author":"Kalakenger S.","year":"2024","unstructured":"Kalakenger S.; Yildiz Arslan S.; Turhan F.; Heterologous expression of codon-optimized azurin transferred by magnetofection method in MCF-10A cells. Mol Biotechnol  2024,66(6),1434-1445","journal-title":"Mol Biotechnol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.sjbs.2020.04.007","volume":"27","author":"Ghasemi-Dehkordi P.","year":"2020","unstructured":"Ghasemi-Dehkordi P.; Doosti A.; Jami M.S.; The functions of azurin of Pseudomonas aeruginosa and human mammaglobin-A on proapoptotic and cell cycle regulatory genes expression in the MCF-7 breast cancer cell line. Saudi J Biol Sci  2020,27(9),2308-2317","journal-title":"Saudi J Biol Sci"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10495-024-02026-4","author":"Solak K.","year":"2024","unstructured":"Solak K.; Yildiz Arslan S.; Acar M.; Combination of magnetic hyperthermia and gene therapy for breast cancer. Apoptosis  2024,1-18","journal-title":"Apoptosis"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.3390\/ijms25116063","volume":"25","author":"Mello D.B.","year":"2024","unstructured":"Mello D.B.; Mesquita F.C.P.; Silva dos Santos D.; Mesenchymal stromal cell-based products: Challenges and clinical therapeutic options. Int J Mol Sci  2024,25(11),6063","journal-title":"Int J Mol Sci"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/biom14070734","volume":"14","author":"Gil-Chinchilla J.I.","year":"2024","unstructured":"Gil-Chinchilla J.I.; Zapata A.G.; Moraleda J.M.; Garc\u00eda-Bernal D.; Bioengineered mesenchymal stem\/stromal cells in anti-cancer therapy: Current trends and future prospects. Biomolecules  2024,14(7),734","journal-title":"Biomolecules"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1080\/1061186X.2024.2347356","volume":"32","author":"Waqar M.A.","year":"2024","unstructured":"Waqar M.A.; Zaman M.; Khan R.; Shafeeq Ur Rahman M.; Majeed I.; Navigating the tumor microenvironment: Mesenchymal stem cell-mediated delivery of anticancer agents. J Drug Target  2024,32(6),624-634","journal-title":"J Drug Target"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.3390\/cancers15133388","volume":"15","author":"Boltman T.","year":"2023","unstructured":"Boltman T.; Meyer M.; Ekpo O.; Diagnostic and therapeutic approaches for glioblastoma and neuroblastoma cancers using chlorotoxin nanoparticles. Cancers  2023,15(13),3388","journal-title":"Cancers"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41419-023-05732-0","volume":"14","author":"Li J.","year":"2023","unstructured":"Li J.; Sun Y.; Zhao X.; Radiation induces IRAK1 expression to promote radioresistance by suppressing autophagic cell death via decreasing the ubiquitination of PRDX1 in glioma cells. Cell Death Dis  2023,14(4),259","journal-title":"Cell Death Dis"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1038\/s41388-020-1250-3","volume":"39","author":"Hutchinson M.K.N.D.","year":"2020","unstructured":"Hutchinson M.K.N.D.; Mierzwa M.; D\u2019Silva N.J.; Radiation resistance in head and neck squamous cell carcinoma: Dire need for an appropriate sensitizer. Oncogene  2020,39(18),3638-3649","journal-title":"Oncogene"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"n1560","DOI":"10.1136\/bmj.n1560","volume":"374","author":"McKinnon C.","year":"2021","unstructured":"McKinnon C.; Nandhabalan M.; Murray S.A.; Plaha P.; Glioblastoma: Clinical presentation, diagnosis, and management. BMJ  2021,374(1560),n1560","journal-title":"BMJ"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1021\/acs.molpharmaceut.4c00604","volume":"21","author":"Culkins C.","year":"2024","unstructured":"Culkins C.; Adomanis R.; Phan N.; Unlocking the gates: Therapeutic agents for noninvasive drug delivery across the blood-brain barrier. Mol Pharm  2024,21(11),5430-5454","journal-title":"Mol Pharm"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/bjc.2013.74","volume":"108","author":"Warso M.A.","year":"2013","unstructured":"Warso M.A.; Richards J.M.; Mehta D.; A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer  2013,108(5),1061-1070","journal-title":"Br J Cancer"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/neuonc\/now047","volume":"18","author":"Lulla R.R.","year":"2016","unstructured":"Lulla R.R.; Goldman S.; Yamada T.; Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A pediatric brain tumor consortium study. Neuro-oncol  2016,18(9),1319-1325","journal-title":"Neuro-oncol"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"vdad042","DOI":"10.1093\/noajnl\/vdad042","volume":"5","author":"Mander S.","year":"2023","unstructured":"Mander S.; Gorman G.S.; Coward L.U.; The brain-penetrant cell-cycle inhibitor p28 sensitizes brain metastases to DNA-damaging agents. Neurooncol Adv  2023,5(1),vdad042","journal-title":"Neurooncol Adv"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/molecules25040874","volume":"25","author":"Majerova P.","year":"2020","unstructured":"Majerova P.; Hanes J.; Olesova D.; Sinsky J.; Pilipcinec E.; Kovac A.; Novel blood\u2013brain barrier shuttle peptides discovered through the phage display method. Molecules  2020,25(4),874","journal-title":"Molecules"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"2400081","DOI":"10.1002\/smsc.202400081","volume":"4","author":"Ye Z.","year":"2024","unstructured":"Ye Z.; Sheu W.C.; Qu H.; Autocatalytic, brain tumor-targeting delivery of bardoxolone methyl self-assembled nanoparticles for glioblastoma treatment. Small Sci  2024,4(8),2400081","journal-title":"Small Sci"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ctm2.492","volume":"11","author":"Du T.","year":"2021","unstructured":"Du T.; Gao J.; Li P.; Pyroptosis, metabolism, and tumor immune microenvironment. Clin Transl Med  2021,11(8),492","journal-title":"Clin Transl Med"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41423-022-00905-x","volume":"19","author":"Wei X.","year":"2022","unstructured":"Wei X.; Xie F.; Zhou X.; Role of pyroptosis in inflammation and cancer. Cell Mol Immunol  2022,19(9),971-992","journal-title":"Cell Mol Immunol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41392-024-01955-5","volume":"9","author":"Liu Z.","year":"2024","unstructured":"Liu Z.; Chen J.; Ren Y.; Multi-stage mechanisms of tumor metastasis and therapeutic strategies. Signal Transduct Target Ther  2024,9(1),270","journal-title":"Signal Transduct Target Ther"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"2300148","DOI":"10.1002\/sstr.202300148","volume":"5","author":"Xiang Y.","year":"2024","unstructured":"Xiang Y.; Li Z.; Pan D.; Gong Q.; Luo K.; Liu Y.; Challenges and opportunities of nanomedicine: Novel comprehensive approaches for brain metastasis. Small Struct  2024,5(2),2300148","journal-title":"Small Struct"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.3389\/fmicb.2018.02915","volume":"9","author":"Baarda B.I.","year":"2018","unstructured":"Baarda B.I.; Zielke R.A.; Jerse A.E.; Sikora A.E.; Lipid-modified azurin of Neisseria gonorrhoeae is not surface exposed and does not interact with the nitrite reductase AniA. Front Microbiol  2018,9,2915","journal-title":"Front Microbiol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.4161\/cc.5.15.2991","volume":"5","author":"Hong C.S.","year":"2006","unstructured":"Hong C.S.; Yamada T.; Hashimoto W.; Fialho A.M.; Das Gupta T.K.; Chakrabarty A.M.; Disrupting the entry barrier and attacking brain tumors: The role of the Neisseria H.8 epitope and the Laz protein. Cell Cycle  2006,5(15),1633-1641","journal-title":"Cell Cycle"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13568-020-00995-8","volume":"10","author":"Mansour M.","year":"2020","unstructured":"Mansour M.; Ismail S.; Abou-Aisha K.; Bacterial delivery of the anti-tumor azurin-like protein Laz to glioblastoma cells. AMB Express  2020,10(1),59","journal-title":"AMB Express"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501415032251108152158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/249980\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501415032251108152158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:41:17Z","timestamp":1782128477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/249980\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":185,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501415032251108152158","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}